Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer
April 6, 2020 10:00 amBy Jason M. Broderick
Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.1
The 3-arm … Read more